id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0610-0021,FDA,FDA-2008-D-0610,Guidance Documents Related to Coronavirus Disease 2019 (COVID–19),Notice,General Notice,2023-03-13T04:00:00Z,2023,3,2023-03-13T04:00:00Z,,2023-03-13T14:07:53Z,2023-05094,0,0,090000648579b2d6
FDA-2008-D-0610-0020,FDA,FDA-2008-D-0610,Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic - Guidance for Industry,Other,Guidance,2020-05-08T04:00:00Z,2020,5,2020-05-08T04:00:00Z,,2024-12-18T13:51:32Z,,1,0,0900006484591e76
FDA-2008-D-0610-0018,FDA,FDA-2008-D-0610,"Postmarketing Adverse Event Reporting for Medical Products and Dietary
Supplements During a Pandemic; Guidance for Industry",Other,Guidance,2020-03-19T04:00:00Z,2020,3,2020-03-19T04:00:00Z,,2024-11-12T23:18:22Z,,1,0,0900006484465441
FDA-2008-D-0610-0017,FDA,FDA-2008-D-0610,Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic; Guidance for Industry,Other,,2020-03-19T00:00:00Z,2020,3,,,2020-04-21T06:12:28Z,,0,1,090000648445772a
FDA-2008-D-0610-0016,FDA,FDA-2008-D-0610,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals",Notice,Notice of Approval,2018-06-19T04:00:00Z,2018,6,2018-06-19T04:00:00Z,,2018-06-19T18:46:08Z,2018-13098,0,0,090000648342f63c
FDA-2008-D-0610-0015,FDA,FDA-2008-D-0610,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Guidance for
Industry on Postmarketing Adverse Event Reporting for Medical Products
and Dietary Supplements During an Influenza Pandemic",Notice,30 Day Proposed Information Collection,2018-04-09T04:00:00Z,2018,4,2018-04-09T04:00:00Z,2018-05-10T03:59:59Z,2018-04-09T15:36:56Z,2018-07154,0,0,09000064830dd395
FDA-2008-D-0610-0013,FDA,FDA-2008-D-0610,"Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an 
Influenza Pandemic",Notice,60 Day Proposed Information Collection,2017-10-31T04:00:00Z,2017,10,2017-10-31T04:00:00Z,2018-01-03T04:59:59Z,2017-11-01T01:03:17Z,2017-23659,0,0,0900006482c28640
FDA-2008-D-0610-0012,FDA,FDA-2008-D-0610,Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic,Other,Guidance,2012-02-24T05:00:00Z,2012,2,2012-02-24T05:00:00Z,,2012-02-24T15:11:42Z,,0,0,0900006480fc051a
FDA-2008-D-0610-0011,FDA,FDA-2008-D-0610,Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability,Notice,Notice of Availability,2012-02-24T05:00:00Z,2012,2,2012-02-24T05:00:00Z,,2012-02-24T14:57:14Z,2012-04288,0,0,0900006480fc01ae
FDA-2008-D-0610-0010,FDA,FDA-2008-D-0610,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Draft Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products, etc.",Notice,General Notice,2011-06-24T04:00:00Z,2011,6,2011-06-24T04:00:00Z,2011-07-26T03:59:59Z,2011-06-24T18:53:04Z,2011-15799,0,0,0900006480eb3446
FDA-2008-D-0610-0009,FDA,FDA-2008-D-0610,Guidance for Industry Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic,Other,GDL-Guidance (Supporting and Related Materials),2011-01-10T05:00:00Z,2011,1,2011-01-10T05:00:00Z,2011-03-09T04:59:59Z,2020-03-19T19:31:38Z,,0,0,0900006480bc6e66
FDA-2008-D-0610-0008,FDA,FDA-2008-D-0610,Draft Guidance for Industry; Availability Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic,Notice,NAD-Notice of Availability of Data,2011-01-07T05:00:00Z,2011,1,2011-01-07T05:00:00Z,2011-03-09T04:59:59Z,2011-03-03T20:47:47Z,2011-00094,0,0,0900006480bc6d37
FDA-2008-D-0610-0006,FDA,FDA-2008-D-0610,See FDA-2008-D-0610-0004,Supporting & Related Material,C-Comment (Supporting and Related Material),2009-02-20T05:00:00Z,2009,2,,,2009-02-20T16:38:45Z,,0,0,090000648085cb0a
FDA-2008-D-0610-0002,FDA,FDA-2008-D-0610,Guidance for Industry - Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic - Draft Guidance,Other,GDL-Guidance (Supporting and Related Materials),2008-12-16T05:00:00Z,2008,12,,,2009-02-19T17:57:41Z,,0,0,09000064807ddc44
FDA-2008-D-0610-0001,FDA,FDA-2008-D-0610,Draft Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability,Notice,NAD-Notice of Availability of Data,2008-12-16T05:00:00Z,2008,12,2008-12-16T05:00:00Z,2009-02-18T04:59:59Z,2009-02-19T17:59:49Z,,0,0,09000064807ddbf2